Here are 1-3 brief analogies for Tonix Pharmaceuticals (TNXP):

• A development-stage pharmaceutical company, like a much smaller Pfizer or Merck that is entirely focused on getting its experimental drugs approved rather than selling established products.
• An early-stage biotech company, much like Amgen or Gilead were in their beginnings, focused on discovering and developing new medicines rather than having a portfolio of currently marketed drugs.
• A smaller, specialized pharmaceutical company, akin to an early Biogen or Vertex Pharmaceuticals, working to bring new treatments to market for specific conditions.

• TNX-102 SL: A sublingual tablet formulation of cyclobenzaprine, currently in development for disorders such as Long COVID, fibromyalgia, and PTSD.
• TNX-1300: An investigational recombinant enzyme designed to degrade cocaine in the bloodstream, intended for the treatment of acute cocaine intoxication.
• TNX-1800 (Recombinant horsepox vaccine): A live attenuated recombinant horsepox virus vaccine candidate being developed for the prevention of smallpox and mpox.

Tonix Pharmaceuticals (TNXP) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative pharmaceutical products. As a clinical-stage company, Tonix Pharmaceuticals does not currently have any major commercialized products on the market generating significant sales revenue to traditional customers (either other companies or individuals).

Therefore, Tonix Pharmaceuticals does not have major customers in the traditional sense of entities purchasing its drugs. Its operations are primarily focused on research and development, clinical trials, and seeking regulatory approvals for its drug candidates. Revenue, when generated, typically comes from investments, grants, or potential future licensing agreements, rather than product sales.

• FUJIFILM Corporation (Symbol: FUJIY)
• Jubilant HollisterStier LLC
• Lonza Group AG (Symbol: LZAGF)
• Thermo Fisher Scientific Inc. (Symbol: TMO)

Seth Lederman, M.D. Co-Founder, CEO & Chairman

Dr. Lederman is a physician, scientist, and entrepreneur, and the co-founder of Tonix Pharmaceuticals. Prior to Tonix, he founded Targent Pharmaceuticals, which developed late-stage oncology drugs. Targent's assets, including levoleucovorin, were acquired by Spectrum Pharmaceuticals, which marketed it as Fusilev®. He also founded VelaVa Pharmaceuticals. Dr. Lederman previously served as an Associate Professor at Columbia University for two decades, where he directed basic science research in molecular immunology, infectious diseases, and the development of therapeutics for autoimmune diseases.

Bradley Saenger, CPA Chief Financial Officer

Mr. Saenger joined Tonix Pharmaceuticals in May 2014 and was promoted to Chief Financial Officer in February 2016. He possesses over 10 years of experience in large publicly traded companies and an additional 10 years in public accounting. His prior experience includes leadership roles as an Associate Director of Accounting at Vertex Pharmaceuticals, Inc. and as a Manager of Corporate Accounting and Consolidations at Alere Inc. He also worked as a financial consultant for Shire Pharmaceuticals and Stewart Health Care System, and for PricewaterhouseCoopers LLP.

Gregory Sullivan, M.D. Chief Medical Officer

Dr. Sullivan serves as the Chief Medical Officer at Tonix Pharmaceuticals, where he is responsible for leading clinical development efforts across a diverse central nervous system (CNS) portfolio. Before joining Tonix, he spent over a decade as an Assistant Professor of Clinical Psychiatry at Columbia University and as a Research Scientist at the New York State Psychiatric Institute (NYSPI), where he was a principal or co-investigator on numerous NIH- and foundation-sponsored clinical studies. He has authored or co-authored more than 50 peer-reviewed articles and book chapters.

Jessica Edgar Morris Chief Operating Officer

Ms. Morris holds the position of Chief Operating Officer at Tonix Pharmaceuticals, having been part of the senior management team since 2018.

Siobhan Fogarty, B.Sc., M.Sc.(QP) Chief Technical Officer

Ms. Fogarty is the Chief Technical Officer at Tonix Pharmaceuticals. She is also identified as the Executive Vice President, Product Development.

The rapid saturation and maturation of the COVID-19 vaccine market, combined with evolving public health priorities and declining demand for novel vaccine platforms, poses a significant threat to the commercial viability of Tonix Pharmaceuticals' COVID-19 vaccine candidates (TNX-1800 and TNX-1850). The dominance of established market leaders and widespread existing vaccination coverage have fundamentally altered the landscape, making it exceptionally difficult for new entrants to secure substantial market share or generate significant revenue, regardless of potential efficacy.

Tonix Pharmaceuticals has several products and product candidates with varying addressable markets:

• Tonmya (TNX-102 SL) for Fibromyalgia: The global market for fibromyalgia treatments is projected to reach $4.13 billion by 2032. In the U.S., over 10 million adults are affected by fibromyalgia.
• TNX-1300 for Cocaine Intoxication: There is currently no FDA-approved treatment for cocaine intoxication. In 2020, over 5 million adults in the U.S. reported current cocaine use. In 2022, cocaine overdose deaths in the U.S. reached 27,569 individuals.
• TNX-801 for Mpox and Smallpox: As a vaccine candidate for mpox and smallpox, TNX-801 addresses infectious diseases. Clade II mpox has become endemic in the United States, with over 30,000 cases reported since May 2022. The market region for TNX-801 includes global potential, with a Phase 1 clinical study planned in Kenya.
• TNX-1500 for Organ Transplant Rejection / Autoimmune Disorders: null
• TNX-2900 for Prader-Willi Syndrome: null
• Zembrace SymTouch and Tosymra for Acute Migraine: null

Tonix Pharmaceuticals (TNXP) is poised for potential revenue growth over the next 2-3 years, primarily driven by the commercialization of its lead product candidate and the advancement of its diverse pipeline. The key expected drivers include:

1. Commercial Launch and Market Penetration of Tonmya (TNX-102 SL) for Fibromyalgia

   The most significant and immediate driver of future revenue growth for Tonix Pharmaceuticals is the commercial launch and subsequent market penetration of Tonmya (TNX-102 SL) for the management of fibromyalgia. The U.S. Food and Drug Administration (FDA) approved Tonmya in August 2025, marking the first new fibromyalgia therapy in over 15 years. The commercial launch is scheduled to commence before the end of November 2025. Analysts project that if approved, TNX-102 SL could generate substantial sales, with some estimating $300 million in Year 1 sales. This product addresses a critical unmet medical need in a large patient population, positioning it for significant market capture.

2. Advancement and Potential Commercialization of Immunology Pipeline Candidates, particularly TNX-1500

   Tonix's immunology pipeline, especially TNX-1500, a next-generation anti-CD40 ligand monoclonal antibody, represents another key driver. TNX-1500 is being developed for the prevention of organ transplant rejection and the treatment of autoimmune diseases. The company has reported positive preclinical and Phase 1 study results, supporting its progression to Phase 2 trials. The successful development and eventual commercialization of TNX-1500 could open significant revenue streams in large and growing therapeutic areas.

3. Development and Potential Commercialization of Infectious Disease Candidates like TNX-801 and TNX-4800

   The company's infectious disease portfolio, particularly TNX-801 (a vaccine for mpox and smallpox) and TNX-4800 (a monoclonal antibody for Lyme Disease), also presents significant future revenue opportunities. TNX-801 has received government grants and shown promising immune protection in preclinical trials. Tonix plans to initiate an adaptive Phase 2/3 study for TNX-4800 during tick season in 2027, addressing a lack of FDA-approved prophylactics for Lyme Disease. These programs benefit from addressing public health needs and potential government funding or procurement contracts.

4. Expansion of TNX-102 SL to New Indications, such as Major Depressive Disorder (MDD)

   Beyond fibromyalgia, Tonix is also developing TNX-102 SL for other indications, notably Major Depressive Disorder (MDD). Following a positive Type B Pre-Investigational New Drug (IND) meeting with the FDA in August 2025 and the filing of an IND in October 2025, Tonix intends to initiate a Phase 2 study for TNX-102 SL in MDD mid-year 2026. Expanding the indications for their lead compound could significantly broaden its market potential and drive additional revenue growth in the future.

Share Repurchases

• On May 31, 2022, Tonix Pharmaceuticals' Board of Directors approved a share repurchase program authorizing the company to repurchase up to $12.5 million of its outstanding common stock.
• On September 6, 2024, the Board authorized a new share repurchase program for up to $10 million of its common stock.
• During the first half of 2025, the company repurchased 400,000 shares of common stock for approximately $5.9 million under the 2024 share repurchase program.

Share Issuance

• Tonix Pharmaceuticals completed public and registered direct offerings in February and July 2020, raising approximately $7.5 million and $10.5 million, respectively.
• In February 2021, the company closed a registered direct offering, generating gross proceeds of approximately $70.0 million.
• From July 2024 to the fourth quarter of 2025, Tonix raised substantial capital through various equity offerings, including $4.0 million in July 2024, $59.8 million in net proceeds during Q1 2025, $9.9 million in Q2 2025, $51.5 million in Q3 2025, and $34.7 million in net proceeds in Q4 2025, while also increasing its at-the-market (ATM) offering limit to $250.0 million.

Inbound Investments

• In October 2022, Tonix Pharmaceuticals secured $15.0 million from institutional investors through a private placement of Series A and Series B Preferred Stock.
• The company has a contract with the U.S. Department of Defense (DoD)'s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years for the development of TNX-4200, a broad-spectrum antiviral agent.
• Tonix was also awarded a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of its mpox vaccine candidate, TNX-801.

Outbound Investments

• In June 2023, Tonix Pharmaceuticals completed a Corporate Asset Purchase of Neurology Migraine Products from Dr. Reddy's.
• As of November 2025, Tonix Pharma has made no other significant outbound investments or acquisitions.

Capital Expenditures

• Capital expenditures significantly decreased from $29.1 million in 2023 to approximately $0.1 million in 2024.
• For the quarter ended June 30, 2024, capital expenditures were approximately $0, a decrease from $24.0 million for the same period in 2023.
• The company anticipates its cash resources and equity proceeds will fund planned operating and capital expenditures into the first quarter of 2027, with a primary focus on working capital, general corporate purposes, and preparing the New Drug Application (NDA) for Tonmya™ (TNX-102 SL) for fibromyalgia.